- In October 2024, Mallinckrodt plc, a global specialty pharmaceutical company, announced a poster presentation on TERLIVAZ® (terlipressin) for injection at Kidney Week 2024. The presentation focused on its use in patients with hepatorenal syndrome (HRS) experiencing rapid kidney function decline. The event took place during the annual meeting of the American Society of Nephrology (ASN) in San Diego from October 23-27, 2024
Frequently Asked Questions
The market is segmented based on Segmentation, By Type (Type 1 Hepatorenal Syndrome, Type 2 Hepatorenal Syndrome, and Others), Diagnosis (Complete Blood Cell Count, Liver Function Tests, Urinalysis and Urine Electrolytes,, and Others), Medication (Vasopressin Analogues, Sympathomimetic Agents, Plasma Volume Expanders, and Others), Surgical Therapies (Peritoneovenous Shunting, Surgical Shunts, Liver Transplantation, and Others), Route of Administration (Oral, Injectable, and Others), End Users (Hospitals, Homecare, Specialty Clinics, and Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, and Others) – Industry Trends and Forecast to 2032
.
The Global Hepatorenal Syndrome Market size was valued at USD 1.44 USD Billion in 2024.
The Global Hepatorenal Syndrome Market is projected to grow at a CAGR of 7.04% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America..
